Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

Similar articles for PubMed (Select 19858772)

1.

Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets.

Puthanakit T, Chokephaibulkit K, Suntarattiwong P, Gorowara M, Leawsrisuk P, Suwanlerk T, Boonrak P, Ruxrungtham K.

Pediatr Infect Dis J. 2010 Jan;29(1):79-82. doi: 10.1097/INF.0b013e3181b21040.

PMID:
19858772
2.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

3.

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.

Ther Drug Monit. 2007 Oct;29(5):560-5.

PMID:
17898644
4.

Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

Resino S, Bellón JM, Ramos JT, Navarro ML, Martín-Fontelos P, Cabrero E, Muñoz-Fernández MA.

Pediatr Infect Dis J. 2004 Oct;23(10):923-30.

PMID:
15602192
5.

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10. Epub 2011 May 2.

6.

Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.

Falkensammer B, Fasser W, Scherer K, Zemann A, Parson W, Ulmer H, Dierich MP, Stoiber H.

Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):145-54.

PMID:
15698519
7.

Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C.

J Antimicrob Chemother. 2006 Jun;57(6):1168-71. Epub 2006 Apr 10.

8.

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.

Antivir Ther. 2007;12(4):453-8.

PMID:
17668553
9.

Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.

van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K.

Antivir Ther. 2009;14(7):1001-4. doi: 10.3851/IMP1410.

PMID:
19918104
10.

Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C.

Antivir Ther. 2009;14(4):603-6.

PMID:
19578247
11.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
12.

Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.

van der Flier M, Verweel G, van der Knaap LC, van Jaarsveld P, Driessen GJ, van der Lee M, Hartwig NG, Burger DM.

Antivir Ther. 2008;13(8):1087-90.

PMID:
19195335
13.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.

Int J Antimicrob Agents. 2005 Jul;26(1):88-91.

PMID:
15878262
14.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

15.

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team.

Antivir Ther. 2009;14(2):241-8.

PMID:
19430099
16.

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.

PMID:
16856617
17.

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):566-9. doi: 10.1097/QAI.0b013e3181642257.

PMID:
18197120
18.

Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.

DiCenzo R, DiFrancesco R, Cruttenden K, Donnelly J, Schifitto G.

Ann Pharmacother. 2009 Dec;43(12):1972-7. doi: 10.1345/aph.1M399. Epub 2009 Nov 24.

PMID:
19934383
19.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

20.

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A.

Antivir Ther. 2004 Aug;9(4):537-43.

PMID:
15456085
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk